Youngs Advisory Group buys $251,998 stake in OraSure Technologies (OSUR)

OraSure Technologies (OSUR) : Youngs Advisory Group scooped up 10,706 additional shares in OraSure Technologies during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 39,009 shares of OraSure Technologies which is valued at $251,998.OraSure Technologies makes up approximately 0.21% of Youngs Advisory Group’s portfolio.

Other Hedge Funds, Including , Acadian Asset Management boosted its stake in OSUR in the latest quarter, The investment management firm added 150,526 additional shares and now holds a total of 1,257,995 shares of OraSure Technologies which is valued at $8,126,648. OraSure Technologies makes up approx 0.04% of Acadian Asset Management’s portfolio. Fox Run Management L.l.c. sold out all of its stake in OSUR during the most recent quarter. The investment firm sold 16,800 shares of OSUR which is valued $108,528.Cutler Group Lp reduced its stake in OSUR by selling 1,900 shares or 13.03% in the most recent quarter. The Hedge Fund company now holds 12,681 shares of OSUR which is valued at $82,046. OraSure Technologies makes up approx 0.01% of Cutler Group Lp’s portfolio. Bnp Paribas Arbitrage Sa added OSUR to its portfolio by purchasing 2,094 company shares during the most recent quarter which is valued at $13,485.

OraSure Technologies opened for trading at $6.45 and hit $6.525 on the upside on Wednesday, eventually ending the session at $6.46, with a gain of 0.16% or 0.01 points. The heightened volatility saw the trading volume jump to 2,39,735 shares. Company has a market cap of $358 M.

On the company’s financial health, OraSure Technologies reported $0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.02. The company had revenue of $29.10 million for the quarter, compared to analysts expectations of $28.82 million. The company’s revenue was up 7.4% compared to the same quarter last year.

Many Wall Street Analysts have commented on OraSure Technologies. OraSure Technologies was Downgraded by Raymond James to ” Mkt Perform” on Jun 13, 2016.

OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.

Leave a Reply

OraSure Technologies - Is it time to Sell?

Top Brokerage Firms are advising their investors on OraSure Technologies. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.